I Have Read the HIPO Code of Conduct and Agree to the Stated Terms and Conditions

Heidelberg Center for Personalized Oncology

/ Project ID:
(Provided by HIPO)
1. / Project Overview
1.1 / Applicant(s)
(Please include all applicants). / Name: Title:
Department:
Address:
Tel.-Nr.:
Fax:
Email:
Name: Title:
Department:
Address:
Tel.-Nr.:
Fax:
Email:
1.2 / Project Title
1.3 / Summary of Project
1.4 / High-Throughput Technologies (Sample Numbers) / HIPO / Whole Genome
Exome
Transcriptome
Bisulfite Seq (WGBS)
ChIP
POP / SNP
Expression Profiling
450K
Others, please specify:
1.5 / Matching Funds from External Sources / €
2. / Project Information
2.1 / Background and Significance
(0.5 -1 page)
2.2 / Rationale
( 0.5- 1 page)
2.3 / Research Design
(0.5 - 1 page). Please state your detailed work plan!
3. / Workflow
NCT MASTER Informed Consent available for all Samples / Yes
Others Please specify:
3A / Sample Preparation
3A.1 / Number of Provided Samples or Analytes / Tumor Samples
Number of Samples
Type (e.g. tissue, DNA, blood, FFPE)
Min. Tumor Cell Content
Germline Control
Number of Samples
Type (e.g. tissue, DNA, blood)
Others
Number of Samples
Type (e.g. liquid biopsy)
3A.2 / Histological Diagnosis Provided by HIPO/POP
(Institute of Pathology) / Yes
No
3A.3 / Analytes Isolation in SPL* required / No
DNA
RNA
Others , please specify: / Number of Samples
Number of Samples
Number of Samples
*QC and Submission of Samples have to be done exclusively by the Sample Processing Lab (SPL).
3B / Molecular and Bioinformatics Analysis
3B.1 / Whole Genome / Number of Samples
Number of Lanes / HIPO-STD (3 lanes/sample)
other:
Person Responsible for Bioinformatic Analysis
3B.2 / Exome / Number of Samples
Number of Lanes / HIPO-STD (3 s.p.l. (tumor), 4 s.p.l. (ctrl))
other:
incl. UTR / No Yes
Kit / HIPO-STD (Agilent SureSelect XT Version 5)
other:
Person Responsible for Bioinformatic Analysis
3B.3 / Transcriptome / Number of Samples
Technique / polyA-RNA Seq.
other:
incl. small RNA / No Yes please specify:
Number of Reads / polyA-STD (40 Mio./ 2,5 samples/lane)
other:
Person Responsible for Bioinformatic Analysis
3B.4 / SNP Genotyping / Number of Samples
Array-Type / Human CytoSNP-12
other:
Person Responsible for Bioinformatic Analysis
3B.5 / Expression Profiling / Number of Samples
Array-Type / Human HT-12 beadarray
other:
Person Responsible for Bioinformatic Analysis
3B.6 / Epigenomes / Number of Samples
Technique / 450K
Whole Genome Bisulfite Sequencing
Number of Lanes (if applicable)
Person Responsible for Bioinformatic Analysis
3B.7 / ChIP / Number of Samples / Tumor: Control:
Marks
(HIPO-Standard Marks are highlighted) / H3
H3K4me1
H3K4me3
H3K9ac
H3K9me3
H3S10p
H3K14ac
H3K27ac
H3K27me3
H3K36me3
H4
H4K16ac
H4K20me3
other (Please specify):
TOTAL ChIPs:
TOTAL Lanes:
Sequencing Type / HIPO-STD (50 bp Single Read, 5 s.p.l.)
other (Please specify)
Person Responsible for Bioinformatic Analysis
3B.8 / Others / Number of Samples
Technique
Additional Information (e.g. estimated cost per sample)
Person Responsible for Bioinformatic Analysis
3C / Data Access (Bioinformatics, PIs)
3C.1 / Request for Data Access
Please list all scientists getting access to data (including E-Mail addresses)
3D / Clinical Data
3D.1 / Patient, Diagnostic, Clinical and Treatment Data / Contact Person (including E-Mail address):
Follow up:
4. Additional Comments

Signatures

□ I have read the HIPO Code of Conduct and agree to the stated terms and conditions.

□ I agree to inform the HIPO board of directors about the intention to submit publications 10 days in advance. Publication criteria should be agreed upon within the respective project team. It is expected that the HIPO/POP organizing parties are considered in the usual academic manner.

Date: Name: Signature:

Date: Name: Signature:

□ I am aware that I am responsible to ensure that all patients included in this study have signed the NCT-MASTER consent or an equivalent other consent form that allows for the applied genetic and bioinformatics analyses as well as the storage of data.

□ If the study uses a patient consent other than NCT MASTER, I am responsible to ensure the compliance with data storage guidelines, especially time limitations of stored data. I will inform the HIPO Data Management Group () about approaching deadlines 3 months in advance.

Date: Name: Signature:

Date: Name: Signature:

Guidelines

Please submit

1.  Electronically as WORD-document to one of the coordinators (see contact details below)

2.  After official acceptance send a signed version of the proposal to one of the coordinators

3.  Please note: QC and Submission of Samples have to be done exclusively by the Sample Processing Lab () or CHARM (for ChIP) ().

Contacts

HIPO-Coordinators:
Dr. Katja Beck
Dr. Janna Kirchhof
DKFZ - German Cancer Research Center
Abteilung Molekulare Genetik (Prof. Lichter)
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: ++49 6221 42 4579
Fax: ++49 6221 42 4639
Email:
/ POP-Coordinator:
Dr. Daniela Richter
Nationales Centrum für Tumorerkrankungen (NCT)
Abteilung Translationale Onkologie (Prof. von Kalle)
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 (0) 6221 56-37819
Fax: +49 (0) 6221 56-6967
Email:

Heidelberg Center for Personalized Oncology 1

Proposal_Version 5.0